Voyager Therapeutics, Inc.

NasdaqGS:VYGR

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

Location

United States

Market Cap

USD 199.21 M

Share Price

USD 3.30

Avg Daily Volume

460,479

Change (1 day)

-8.33%

Change (1 year)

-62.50%

Change (YTD)

-41.80%

Voyager Therapeutics, Inc. Price to Book Ratio (P/B) on June 13, 2025: 0.64

Voyager Therapeutics, Inc. Price to Book Ratio (P/B) is 0.64 on June 13, 2025, a -68.05% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Voyager Therapeutics, Inc. 52-week low Price to Book Ratio (P/B) is 1.89 on June 13, 2025, which is 193.79% above the current Price to Book Ratio (P/B).
Voyager Therapeutics, Inc. 52-week low Price to Book Ratio (P/B) is 0.51 on June 13, 2025, which is -20.83% below the current Price to Book Ratio (P/B).
Voyager Therapeutics, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 1.06.

Daily

From:

To:

Zoom:

Key data

Date	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)	Enterprise Value to EBITDA (EV/EBITDA)	Free Cash Flow Yield

NasdaqGS: VYGR

Voyager Therapeutics, Inc.

CEO	Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
IPO Date	Nov. 11, 2015
Location	United States
Headquarters	75 Sidney Street
Employees	172
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials

Description

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.